Journal
FRONTIERS IN BIOSCIENCE-LANDMARK
Volume 17, Issue -, Pages 2698-2724Publisher
IMR PRESS
DOI: 10.2741/4081
Keywords
EGFR; HER-2; IGF-IR; Small Molecules; Antibodies; Pancreatic Cancer; Review
Categories
Funding
- Kingston University London
- Ralph Bates Pancreatic Cancer Research fund
- Cancer Vaccine Institute
Ask authors/readers for more resources
Pancreatic cancer is still one of the most aggressive and fatal types of human cancer. Survival rates for patients with pancreatic cancer are extremely poor and one major contributing factor is the lack of specific marker(s) for the early detection of pancreatic cancer. Indeed, the great majority of pancreatic cancer cases are diagnosed at an advanced stage of the disease and these patients often have a poor response to treatment with conventional forms of therapy. In this article, we conduct a comprehensive review of the literature on the expression pattern, prognostic significance and predictive value of EGFR family members, IGF-IR and their ligands in pancreatic cancer. We also discuss recent advances in pancreatic cancer treatments and highlight the remaining challenges as well as future opportunities for more effective targeting of such receptors using a combination of growth factor receptor specific monoclonal antibodies, small molecule tyrosine kinase inhibitors and other therapeutic strategies. Such strategies could ultimately help to overcome the development of drug resistance and improve the overall survival rates for patients with pancreatic cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available